Summary

About the company

Baxiva AG entwickelt glycokonjugierte Impfstoffe zur Vorbeugung bakterieller Infektionen. Die Plattform verknüpft serotyp-spezifische bakterielle Polysaccharide chemisch mit virusähnlichen Partikeln (VLPs), um immunogene, multivalente Impfstoffkandidaten gegen gramnegative Krankheitserreger wie Escherichia coli zu erzeugen.

AI-generated

Knowledge

No knowledge articles yet

Once Biocon Biologics Switzerland AG claims this profile, we will publish editorial articles and case studies together here.

Get started

Comparisons

Biocon Biologics Switzerland AG in comparison

Soon

Industry comparisons are coming soon

We are preparing industry comparisons in which Biocon Biologics Switzerland AG will be ranked by reviews, experience and specialisations.